Parabilis Medicines, Inc. PBLS
At closeNov 6, 2026, 4:01 PM EST
After hours · Nov 6, 4:01 PM ET
- YTD
- -9.72%
- 1 year
- -9.72%
- Market cap
- 3.52B
- Revenue (ttm)
- 148.00K
- EPS (ttm)
- -9.51
- Shares out
- 121.95M
- Forward P/E
- -13.05
- YTD return
- -9.72%
- 1-year return
- -9.72%
- Volume
- 629.33K
- Avg volume
- 915.18K
- Open
- 27.88
- Previous close
- 27.88
- Day's range
- 27.11 – 28.87
- 52-week range
- 22.75 – 41.73
- Analysts
- Strong Buy
- Price target
- 41.40 (+45.1%)
- Earnings date
- Nov 12, 2026
5D +0.45 (+1.60%)
Key statistics
- Enterprise value
- 2.37B
- PEG ratio
- 0.00
- Price / sales
- 23813.54
- Price / book
- 3.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 1.12B
- Total debt
- 47.51M
- Return on equity
- 0.00%
- Short % of float
- 7.59%
- 50-day average
- 32.13
- 200-day average
- 32.08
Analyst view
Consensus: strong buy
- Target (low)
- 40.00
- Target (mean)
- 41.40
- Target (high)
- 45.00
- Strong buy0
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.38.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.36 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -0.165 | -2.32 | -2.15 | -1,306.06% |
| May 19, 2026 | Mar 31, 2026 | — | -0.72 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | init | — | Buy |
| Jul 6, 2026 | Guggenheim | init | — | Buy |
| Jul 6, 2026 | Leerink Partners | init | — | Outperform |
| Jul 6, 2026 | B of A Securities | init | — | Buy |
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- parabilismed.com
News
Parabilis Medicines to Participate in Upcoming November Investor Conferences 
HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40 
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday 
Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026 
Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial 
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday 
Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate - Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45
Your note
Sign in to keep a note on PBLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORISY ALEXIS | Director | Conversion of Exercise of derivative security | Jun 10, 2026 | 105,414 |
| FITZGERALD EDWARD M | Director | Conversion of Exercise of derivative security | Jun 10, 2026 | 14,688 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 10, 2026 | 0 |
| LEVY GUY B | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 10, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 21, 2026 | 0 |
| SEBULSKY ALAN M | Director | Purchase | Jun 14, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 23.73% | 28,933,371 | 825.47M | Jun 29, 2026 |
| FMR, LLC | 8.44% | 10,292,735 | 293.65M | Jun 29, 2026 |
| Arch Venture Management, Llc | 5.26% | 6,412,780 | 182.96M | Jun 29, 2026 |
| venBio Partners LLC | 4.32% | 5,266,697 | 150.26M | Jun 29, 2026 |
| Alphabet Inc. | 4.03% | 4,919,498 | 140.35M | Jun 29, 2026 |
| Nextech Invest, Ltd. | 3.82% | 4,663,176 | 133.04M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.92% | 1,121,000 | 31.98M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.84% | 1,027,321 | 29.31M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.66% | 807,764 | 23.05M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.42% | 507,533 | 14.48M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.40% | 486,669 | 13.88M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.39% | 480,209 | 13.70M | Jun 29, 2026 |